

POWER

PEOPLE | INNOVATION | PARTNERSHIP

GERMAN EQUITY FORUM

November 28, 2023

SAFE HARBOR STATEMENT

Forward-looking statements involve risks.

This company presentation contains various statements concerning the future performance of STRATEC. These statements are based on both assumptions and estimates. Although we are convinced that these forward-looking statements are realistic, we can provide no guarantee of this. This is because our assumptions involve risks and uncertainties which could result in a substantial divergence between actual results and those expected.

It is not planned to update these forward-looking statements.

STRATEC AT A GLANCE

- Leading OEM player for automation solutions for the diagnostics industry and translational research
- Three decades of experience in highly regulated healthcare markets and growing technology pool
- Around 1.500 employees worldwide
 - Around 50% allocable to R&D
- Production sites in Germany (HQ), Switzerland, Hungary, Austria and the United States
- High number of systems installed globally
 - Around 15,000 medium to high throughput systems
 - Around 40,000 low throughput systems
- Sales of € 274.6 million in 2022
 - CAGR sales since IPO in 1998: ~14%
- Sales split 2022:
 - Systems 51%
 - Service parts and consumables 32%
 - Development and services 16%
- Dividend payments raised over 19 consecutive years



CORPORATE SOCIAL RESPONSIBILITY



QUALITY MANAGEMENT

Highest quality standards

- Established high-performance, certified quality management system
- Ensuring consistently high product quality
- Strong audit track record (regarding inspections by customers and regulatory authorities)

ENVIRONMENTAL RESPONSIBILITY

Combat climate change

- Greenhouse gas reduction target¹ in-line with Paris agreement
- **STRATEC reduced its total Scope 1 and 2 emissions by 68% since 2019**
- Unavoidable Scope 1 and 2 emissions fully compensated by certified emission reduction projects

SOCIAL RESPONSIBILITY

Secure diverse and inclusive work environment

- Strong policies and measures to promote an open, tolerant and discrimination-free corporate culture
- Extensive occupational health/safety policies and programs



Participant of the UN Global Compact: Further alignment of strategies and operations to the Ten Principles of the UN Global Compact on human rights, labor, environment and anti-corruption / SDGs

¹ 30% absolute reduction of scope 1 and 2 emissions by 2030 (versus 2019)

UNIQUE POSITION WITHIN THE VALUE CHAIN

STRATEC provides instrumentation, consumables, software and automation solutions

- OEM development and manufacturing
- Around 10,000 fully automated analyzer systems manufactured annually
- Wide range of intellectual property rights / broad technology pool

Long market lifecycles lead to longstanding partnerships


- Product lifecycles for a system typically in an area of 12 to 15 years
- Expanding installed base of systems
- Product enhancement and extension drives value / Life cycle management

Long-term contractual setup


- Milestone payments during development stage (linked to agreed development budget and development targets)
- Operating sales during series production stage - minimum volume commitment by partner, firm transfer price)
- Recurring sales from service parts & consumables

→ strong commitment by both partners

Shared responsibilities



Indicative revenue characteristics of an analyzer OEM project



ACTIVE IN FAST GROWING SEGMENTS

IVD MARKET SEGMENTS / IVD MARKET: >100 BILLION USD IN 2021

Focus on market segments with above average complexity and growth

Molecular Diagnostics

- Random access analyzer systems (mid-to-high throughput)
- Smart consumables (multiplexing)
- POC devices (multiplexing) with smart consumables

Immunoassay

- Random access analyzer systems (mid-to-high throughput)
- Classic plastic consumables
- Smart consumables


Hematology & other routine testing

- Decentralized testing solutions
- Veterinary diagnostics
- Plastics


Further specialities / focus areas

- Immunochemistry
- Complex Sample Processing
- Tissue Diagnostics
- Translational Research

IVD market by technologies



IVD market by product group



Source: MarketsandMarkets Research; own estimates

BENEFITTING FROM OUTSOURCING TREND

OUTSOURCED VS IN HOUSE INSTRUMENTATION MARKET

The majority of instrumentation equipment in the IVD market is still developed in-house by diagnostics companies.

Share of outsourced developments has already increased significantly over the last couple of years.

Trend of outsourcing towards specialized players set to continue, due to:

- Engineering of automation solutions often not core competence of diagnostics companies
- Shorter development timeframes due to already existent technology pools
- Guaranteed project budget and firm transfer prices
- Keeping up with regulatory developments easier for specialized players
- Structured processes in order to address end customer needs, such as ease of use, user experience, workflow efficiencies, remote access, serviceability and preventive maintenance

Proportion of outsourced instrumentation developments over time

Past

Ongoing paradigm shift even within the „blue chips“ towards outsourcing



STRONG RECURRING REVENUE BASE


Service parts and consumables (33% of sales)

- Maintenance parts
- Spare parts
- Classic plastic consumables (eg. Pipetting tips, reaction vessels)
- Smart consumables (highly complex cartridges; microfluidics, molding, mastering and coating technologies)

Fueled by growing installed base and increasing complexity

- Continuously growing number of active systems in the lab
- Strong upward trend in the average complexity of systems

Smart consumables



SIMOA™ 24-ASSAY DISC
Quanterix



FLEXIMASS™ - DS MALDI TARGET
Shimadzu Biotech

Service and spare parts




Peristaltic Pump
STRATEC

Classic consumables




Stackable Cuvette
STRATEC

Installed base¹
STRATEC Instrumentation




■ Installed base (number of system)

Installed base¹
Diatron



Sales split 2022



¹ Estimated with the assumption of an average six year replacement cycle in the lab

STRONG LONG-TERM CUSTOMER RELATIONSHIPS

A SELECTION OF STRATEC CUSTOMERS

GLOBAL TOP 20 IVD COMPANIES		Sales 2022 (USD billion)
1.	Roche	18.2
2.	Abbott	16.6
3.	Danaher	10.8
4.	Siemens	6.1
5.	Thermo Fisher	4.8
6.	BECTON DICKINSON	4.7
7.	QuidelOrtho	4.1
8.	bioMérieux	3.2
9.	Sysmex	3.1
10.	HOLOGIC	2.6
11.	mindray	2.5
12.	Exact Sciences	2.1
13.	Illumina	2.1
14.	PerkinElmer	2.0
15.	werfen	1.8
16.	DiaSorin	1.5
17.	BIO-RAD	1.5
18.	Agilent	1.4
19.	Diagnostica Stago	0.9
20.	Seegene	0.7

... And other technology pioneers



■ STRATEC customer ■ Not a STRATEC customer


Source: IVD News / non-public companies estimated / non-reported sector sales estimated

POSITIVE LONG-TERM FINANCIAL PERFORMANCE

KEY FIGURES - TRACK RECORD


Sales

CAGR ~8%



Adjusted EBIT¹

CAGR ~11%




¹ Figures adjusted for comparison; adjusted for depreciation and amortization from purchase price allocation for acquisitions, related integration expenses and other extraordinary effects. Reconciliation to IFRS figures can be found in the respective annual report.


POSITIVE LONG-TERM FINANCIAL PERFORMANCE

KEY FIGURES - TRACK RECORD

Adjusted net income¹ CAGR ~11%



Dividend per share CAGR ~6%



¹ Figures adjusted for comparison; adjusted for depreciation and amortization from purchase price allocation for acquisitions, related integration expenses and other extraordinary effects. Reconciliation to IFRS figures can be found in the respective annual report.

9M/2023 AT A GLANCE

- **Sales -9.1%** at constant-currency to €187.7 million
 - Sales performance still adversely affected by **excess molecular diagnostics capacities** built up during **pandemic**
 - **Market demand** does not yet break through due to **destocking effects** following global supply crisis
 - **Stockholdings** at customers expected to **return to normal levels** at the **beginning/in the middle of 2024**
- **Significant intra-year improvement in profitability** in **Q3/2023** with adjusted **EBIT margin of 14.8 %**
 - **Substantial progress** within initiated **earnings improvement program** (current run rate **ahead of schedule**)
- **Financial guidance for 2023: sales guidance slightly adjusted** and **margin target confirmed**
- **Well-stocked development pipeline** and **significant expansion** of two **major development cooperations**

FINANCIALS AT A GLANCE¹

€ 000s	9M/2023	9M/2022	Change	Q3/2023	Q3/2022	Change
Sales	187,680	207,654	-9.6%	62,674	70,461	-11.1%
Adjusted EBITDA	27,267	48,095	-43.3%	13,370	20,254	-34.0%
Adjusted EBITDA margin (%)	14.5	23.2	-870 bps	21.3	28.7	-740 bps
Adjusted EBIT	16,222	38,067	-57.4%	9,257	16,889	-45.2%
Adjusted EBIT margin (%)	8.6	18.3	-970 bps	14.8	24.0	-920 bps
Adjusted consolidated net income	9,742	29,549	-67.0%	5,682	12,870	-55.9%
Adjusted basic earnings per share (in €)	0.80	2.44	-67.2%	0.47	1.06	-55.7%
Basic earnings per share IFRS (in €)	0.62	2.04	-69.6%	0.42	1.00	-58.0%


bps = basis points

¹ For comparison purposes, adjusted figures have been adjusted to exclude amortization resulting from purchase price allocations in the context of acquisitions and other non-recurring items (advisory expenses and restructuring costs relating to M&A activities and one-off personnel expenses). In the previous year, the figures were additionally adjusted to exclude a provision for expected back payments of tax (including interest payments).

FINANCIAL REVIEW

SALES 9M/2023

Sales in € million



As of September 30


Sales in 9M/2023 -9.6% to € 187.7 million

→ -9.1% at constant currency

- (-) Pandemic related overcapacities within MDx market and still elevated inventory levels at customers
- (-) Low utilization levels within the installed base limits growth with service parts
- (+) Slight growth with development and service sales versus tough prior year base of comparison
- (+) Growing contributions from newly launched systems

FINANCIAL REVIEW

ADJUSTED EBIT AND EBIT MARGIN 9M/2023



9M/2023 adjusted EBIT down by 57.4% yoy to € 16.2 million, margin at 8.6%

- (-) Negative economies of scale
- (-) Product mix effects
- (+) Implemented price adjustments
- (+) Targeted measures in areas of personnel and development

Significant improvement in Q3/2023 with adjusted EBIT margin of 14.8%

As of September 30

FINANCIAL REVIEW

CASH FLOW AND NET DEBT 9M/2023

€ 000s	9M/2023	9M/2022	Change
Cash flow – operating activities	10,709	22,285	-51.9%
Cash flow – investment activities	-45,666	-16,921	n/a
Cash flow – financing activities	26,634	-16,938	n/a
Free cash flow	-34,957	5,364	n/a

€ 000s	9M/2023	FY/2022	Change
Cash	14,315	22,668	-36.8 %
Equity ratio (%)	51.0	56.6	-560 bps
Net debt	131,803	76,619	+72 %

- Operating cash flow burdened by lower operating profitability and still materially inflated inventory levels
- Cash flow from investment activities includes € 27.7 million outflow for Natech Plastics acquisition
- Investment ratio¹ at 7.5% of sales versus 5.8% in 9M/2022 → in-line with full year target corridor of 6.0% to 8.0%
- Net debt / EBITDA² ~3x


¹ Total investments in intangible and tangible assets in % of sales

² Based on EBITDA forecast for 2023


FINANCIAL REVIEW

SALES BY OPERATING DIVISIONS HI/2023

Sales in € million



In % of total sales



As of June 30

CER= Constant exchange rates

EARNINGS IMPROVEMENT PROGRAM*



Focus area	Earnings impact 2024 (pre-tax)	Status
Personnel measures <ul style="list-style-type: none"> – Temporary and partial hiring freeze – Reallocation of resources – Reduction of personnel related consultancy costs, etc. 	+4.0 to +5.0 million €	<ul style="list-style-type: none"> – Hiring freeze implemented since March 2023 – On track to achieve positive earnings impact of around € 4.0 million already in 2023
Focused price adjustment strategies	+5.0 to +8.0 million €	<ul style="list-style-type: none"> – Price increases for major products have become effective as of 1 July 2023
Non-personnel cost reductions and others <ul style="list-style-type: none"> - Procurement optimizations - Product portfolio optimizations - Others 	+1.0 to +2.0 million €	<ul style="list-style-type: none"> – Extended program to optimize procurement structures and processes initiated – First positive effects from logistical measures on the back of improved market environment
TOTAL	+10.0 to +15.0 million €	

*Compared with the original company budget


OUTLOOK

GUIDANCE FOR FISCAL YEAR 2023

- Sales expected to fall slightly short on a constant-currency basis compared to previous year (previously: sales to remain stable or grow slightly)
 - Ongoing and pandemic-related period of subdued developments in the molecular diagnostics instrumentation solutions market
- Adjusted EBIT margin of around 10.0% to 12.0% (2022: 16.4%)
 - Implemented price increases and further progress in the execution of earnings improvement program
- Investments in tangible and intangible assets combined of around 6.0% to 8.0% of sales



APPENDIX



APPENDIX

KEY FIGURES AT A GLANCE¹

IFRS (€ million)	2018	2019	2020	2021	2022
Sales	187.8	214.2	250.1	287.3	274.6
Adjusted EBIT	26.2	29.3	41.7	54.3	45.1
Adjusted EBIT margin (%)	13.9	13.7	16.7	18.9	16.4
Adjusted Consolidated net income	20.2	24.1	35.2	45.1	34.7
Adjusted Earnings per share (€)	1.70	2.01	2.92	3.73	2.86
Dividend per share (€)	0.82	0.84	0.90	0.95	0.97
No. of employees	1,228	1,302	1,319	1,398	1,481
Total assets	275	299	332	369	398
Equity ratio (%)	55.3	53.1	52.0	55.8	56.6
Free cash flow	1.2	-6.4	10.0	43.3	-8.7

¹ Figures adjusted for comparison; adjusted for depreciation and amortization from purchase price allocation for acquisitions, related integration expenses and other extraordinary effects. Reconciliation to IFRS figures can be found in the respective annual report.

APPENDIX

ADJUSTMENTS 9M/2023

€ 000s	9M/2023	9M/2022
Adjusted EBIT	16,222	38,067
Adjustments:		
PPA amortization	-1,713	-2,627
Other ¹	-1,217	0
EBIT	13,292	35,440


¹ Advisory expenses and restructuring costs in connection with M&A activities as well as one-off personnel expenses

€ 000s	9M/2023	9M/2022
Adjusted consolidated net income	9,742	25,549
Adjusted earnings per share in € (basic)	0.80	2.44
Adjustments:		
PPA amortization	-1,713	-2,627
Other ¹	-1,217	0
Taxes on income	714	-2,020
Interest expenses	0	-183
Consolidated net income	7,526	24,719
Earnings per share in € (basic)	0.62	2.04

¹ Advisory expenses and restructuring costs in connection with M&A activities as well as one-off personnel expenses

SHAREHOLDER STRUCTURE

(AS OF: JANUARY 2023)



■ Fixed and family ownership
(incl. their investment companies)

■ Free float

Institutional investors > 3%:

Brown Capital Management

Invesco

Juno Investment Partners

SHARE

IPO

Aug. 1998

Number of shares

12,157,841

Share price (11/20/2023)

€ 44.90

Market capitalization

€ 546 million

CONTACT

STRATEC SE
Gewerbestr. 37
75217 Birkenfeld
Germany

Phone +49 7082 7916-0
Fax +49 7082 7916-999
www.stratec.com

CONTACT

Jan Keppeler, CFA
Head of Investor Relations,
Sustainability & Corporate Communications

Phone +49 7082 7916-6515
j.keppeler@stratec.com



THANK YOU
FOR YOUR
ATTENTION